Immuneering (IMRX) Equity Ratio: 2020-2024
Historic Equity Ratio for Immuneering (IMRX) over the last 4 years, with Sep 2024 value amounting to 0.84.
- Immuneering's Equity Ratio fell 7.82% to 0.84 in Q3 2024 from the same period last year, while for Sep 2024 it was 0.84, marking a year-over-year decrease of 7.82%. This contributed to the annual value of 0.88 for FY2023, which is 1.65% down from last year.
- Immuneering's Equity Ratio amounted to 0.84 in Q3 2024, which was down 2.12% from 0.86 recorded in Q2 2024.
- In the past 5 years, Immuneering's Equity Ratio ranged from a high of 0.96 in Q3 2021 and a low of -0.66 during Q2 2021.
- For the 3-year period, Immuneering's Equity Ratio averaged around 0.90, with its median value being 0.91 (2023).
- As far as peak fluctuations go, Immuneering's Equity Ratio soared by 259.91% in 2021, and later fell by 7.82% in 2024.
- Immuneering's Equity Ratio (Quarterly) stood at -0.59 in 2020, then skyrocketed by 259.91% to 0.94 in 2021, then dropped by 4.06% to 0.90 in 2022, then declined by 1.65% to 0.88 in 2023, then decreased by 7.82% to 0.84 in 2024.
- Its last three reported values are 0.84 in Q3 2024, 0.86 for Q2 2024, and 0.89 during Q1 2024.